TEVA

TEVA PHARMACEUTICAL-SP ADR

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary

TEVA PHARMACEUTICAL-SP ADR (TEVA) is held as common stock by 7 tracked hedge-fund managers, with a combined reported value of ~$234.07M; the largest are Izzy Englander, Ray Dalio, Steven Cohen. 4 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 3 added, 3 trimmed. 10 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.

Attention · MediumThis quarter · Mixed

Common-stock holders74 also report options

Congress trades10

Price$39.81vs quarter-end+17.50%

Sectors0

This quarter's moves

New1

Added3

Trimmed / sold3

Top holder

Izzy Englander

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Stanley DruckenmillerTrim

Value $21.18M0.5% of portfolio624,9992026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Stanley Druckenmiller	2026 Q2	$21.18M	624,999	0.5%	Trim

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinCALL—

Value $95.61M— of portfolio2,822,0002026 Q2

Ken GriffinPUT—

Value $45.66M— of portfolio1,347,6002026 Q2

Izzy EnglanderCALL—

Value $23.28M— of portfolio687,2002026 Q2

Steven CohenPUT—

Value $13.52M— of portfolio399,2002026 Q2

Steven CohenCALL—

Value $3.56M— of portfolio105,2002026 Q2

Paul Tudor JonesPUT—

Value $2.72M— of portfolio80,3002026 Q2

Paul Tudor JonesCALL—

Value $945.3K— of portfolio27,9002026 Q2

Izzy EnglanderPUT—

Value $897.8K— of portfolio26,5002026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Ken GriffinCALL	2026 Q2	$95.61M	2,822,000	—	—
Ken GriffinPUT	2026 Q2	$45.66M	1,347,600	—	—
Izzy EnglanderCALL	2026 Q2	$23.28M	687,200	—	—
Steven CohenPUT	2026 Q2	$13.52M	399,200	—	—
Steven CohenCALL	2026 Q2	$3.56M	105,200	—	—
Paul Tudor JonesPUT	2026 Q2	$2.72M	80,300	—	—
Paul Tudor JonesCALL	2026 Q2	$945.3K	27,900	—	—
Izzy EnglanderPUT	2026 Q2	$897.8K	26,500	—	—

Insider Trading

Officers · directors · Form 4

Open-market purchases and sales (P/S)8

Evan Lippman
EVP, Business Development
Sell$680.3K
18,600 @ $36.57Traded 2026-08-17Filed 2026-08-19
Tal Zvi Zaks
Director
Sell$593
17 @ $34.87Traded 2026-08-05Filed 2026-08-10
Eric A Hughes
See "Remarks"
Sell$892.1K
25,578 @ $34.88Traded 2026-08-03Filed 2026-08-05
Placid Jover
See "Remarks"
Sell$447.4K
12,827 @ $34.88Traded 2026-08-03Filed 2026-08-05
Matthew Shields
EVP, Global Operations
Sell$321.5K
9,989 @ $32.19Traded 2026-06-18Filed 2026-06-22
Eliyahu Sharon Kalif
EVP, Chief Financial Officer
Sell$3.63M
106,563 @ $34.10Traded 2026-06-11Filed 2026-06-16
Richard D Francis
President and CEO
Sell$211.4K
6,153 @ $34.35Traded 2026-06-05Filed 2026-06-08
Matthew Shields
EVP, Global Operations
Sell$532.3K
16,195 @ $32.87Traded 2026-06-03Filed 2026-06-04

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.